Answers are grounded in this paper and cite their sources.
BackgroundWe examined the positive response and clinical usefulness of 14 serum antibodies in patients with squamous cell esophageal carcinoma (ESCC). The Cancer Genome Atlas (TCGA) was used to study the frequency of gene expressions, mutations, and amplification of these 14 antigens, and this database helped investigate the possible effects of antibody induction.MethodsBlood serum from 85 ESCC patients was collected and tested for 14 antibodies using an ELISA assay. The prognosis between positive and negative antibodies were then compared. The antibody panel included Galectin1, HCA25a, HCC-22-5, and HSP70.ResultsPatient serum was positive for all antibodies except VEGF, ranging from 1.18 to 10.59%. Positive rates of Galectin1, HCA25a, HCC-22-5, and HSP70 were more than 10%. TCGA data showed all antigen-related genes had little or no mutation or amplification, so an increase in gene expression effected antibody induction. The positive results from the panel accounted for the positive rate comparable to the combination of CEA and SCC. There was no significant association between the presence of antibodies and disease prognosis.ConclusionsThe presence of Galectin1, HCA25a, HCC-22-5, and HSP70 were 10% higher in ESCC patients. Gene overexpression may be involved in such antibody production. The utility of using these four antibodies compared to conventional tumor markers was shown as a panel. Furthermore, it was confirmed that the combination of this panel and conventional tumor markers significantly improved the positive rate
No takes yet. Share an insight, caveat, or question.
Hoshino et al. (2020) studied this question.